Stay Up to Date
with SHINE

How can cancer treatment become more precise and less harmful to healthy tissue? Radiotheranostics use radioactive isotopes to locate and treat cancer cells at the molecular level. Learn how these therapies work, which isotopes power them, and why expanding isotope supply matters for patient access.

A year of mysterious symptoms. A Stage IV cancer diagnosis. Tumors too large for surgery. But a groundbreaking Lu-177 PRRT trial gave this father of three a fighting chance. Read how precision nuclear medicine transformed an advanced NET cancer diagnosis into remission.

SHINE has completed its acquisition of Lantheus' SPECT business, including the North Billerica SPECT manufacturing facility and diagnostic radiopharmaceutical portfolio. The acquisition adds immediate revenue and operational scale while strengthening isotope supply.

Forty million cancer diagnostic scans depend on isotopes from 1960s-era reactors. Tech Brew covered how fusion technology and other approaches are creating reliable domestic supply chains. Our Chrysalis facility will produce Mo-99 at scale using fusion technology.

Hundreds of clinical trials are testing radiotheranostic cancer treatments worldwide. This guide walks you through how to find them—from understanding radiotheranostics are to finding studies that may be relevant to you and discussing options with your care team.

A new feature in In Business: Madison explores why Wisconsin has become an unlikely fusion epicenter—and why what happens here determines who leads the industry. From SHINE's commercial systems to the Great Lakes Fusion Energy Alliance, the momentum is real and the window is narrow.

Breakthrough cancer treatments need rare isotopes like terbium-161, but global supply is limited. SHINE's successful gadolinium enrichment demonstration opens the path to producing these promising theranostic isotopes at scale. Learn how we did it.

UW-Madison's $19M FIRE award will use our neutron source to test fusion blanket technology under the most intense neutron conditions ever tested. The research provides critical insights the entire fusion industry needs.

We're already making money from fusion technology: we sell neutrons for defense testing and medical isotopes for cancer therapy. Heatmap explores how our revenue-first approach could be the fastest path to fusion energy commercialization.

Utility Dive Article: Major utilities are moving beyond vague promises to concrete fusion partnerships, driven by breakthroughs suggesting commercial fusion power could arrive within 10-15 years. While others chase energy milestones, our revenue-first approach is building the expertise needed to lead this transformation.

PODCAST: Greg Piefer joins the MasterMove podcast to discuss our unconventional path to commercial nuclear fusion energy, the leadership challenges of scaling fusion technology, and why our revenue-first approach is making fusion profitable today.

FORBES article: The U.S. has 90,000 tons of spent nuclear fuel with enough energy to power the nation for years. In his article, Greg Piefer explains why recycling efforts failed before and outlines the practical path to making nuclear truly renewable through disciplined execution and updated policy.

A stretch of southern Wisconsin has quietly become America's nuclear medicine powerhouse. How did a region known for farming and manufacturing attract world-class cancer researchers and cutting-edge medical companies? Find out at this event.

We're celebrating 15 years! World records, regulatory firsts, and cancer-fighting medical isotopes. See how we're making fusion profitable today.

Is fusion 5 years away or 50? Help us bring this critical debate to SXSW 2026. Real timeline answers from fusion leaders. Greg Piefer to joins other experts for the conversation investors and policymakers need to hear. Vote now.